Episode Details

Alnylam Pharmaceuticals just suffered a brutal 26% single-day crash—despite posting a massive 74% revenue jump to $1.17 billion and turning a profit. Why did Wall Street panic? Because management lowered full-year guidance, signaling that early pent-up demand for its blockbuster drug, Amvuttra, is normalizing and the growth curve is flattening out. In this episode of Implied, we break down what happens when a stock is "priced for perfection," how fierce competition from giants like Pfizer plays in, and whether this massive selloff is a biotech trap or a rare buying opportunity. Tune in to make sense of the market's wild reaction!